

## ExpreS2ion enters strategic agreement with DTU for access to the Computerome supercomputer

Hørsholm, Denmark, 7 July 2025 – ExpreS2ion Biotech Holding AB (Nasdaq First North Growth Market: EXPRS2, "ExpreS2ion" or the "Company"), a clinical-stage biotechnology company with a focused portfolio of immunotherapy candidates for infectious diseases and cancer, today announced that it has entered into an Infrastructure-as-a-Service (IaaS) agreement with the Technical University of Denmark (DTU) to gain access to Computerome 2.0, one of Denmark's most advanced high-performance computing (HPC) platforms for secure biomedical data processing.

This agreement enables ExpreS2ion to conduct large-scale bioinformatic analyses in support of its vaccine development programs targeting infectious diseases and cancer. The Computerome platform is optimized for handling sensitive health data under strict GDPR compliance and offers a secure, high-performance computing environment tailored to life science applications.

*"Access to Computerome significantly enhances our bioinformatics infrastructure and enables a more scalable and efficient approach to analysing the increasingly complex data generated in our R&D pipeline," says Bent U. Frandsen, CEO of ExpreS2ion. "This agreement marks an important step in supporting our ongoing innovation in immunotherapy and vaccine development."*

Computerome is a nationally recognised computing infrastructure used by hospitals, universities, and selected private sector partners in Denmark. It is specifically designed to support research within genomics, precision medicine, and life sciences.

The collaboration is expected to support ExpreS2ion's efforts in data-driven decision-making within immunology, sequence analysis, and protein design.

### About ExpreS2ion

ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improve quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit [www.expres2ionbio.com](http://www.expres2ionbio.com).

### For further information about ExpreS2ion, please contact:

Bent U. Frandsen, CEO  
Keith Alexander, CFO  
E-mail: [investor@expres2ionbio.com](mailto:investor@expres2ionbio.com)

### Certified Adviser

Svensk Kapitalmarknadsgranskning AB

*The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company's news distributor, Cision, at the publication of this press release.*